SRNE — Sorrento Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $4.80m
- $73.42m
- $62.84m
- 14
- 55
- 11
- 17
Annual income statement for Sorrento Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 21.2 | 31.4 | 40 | 52.9 | 62.8 |
| Cost of Revenue | |||||
| Gross Profit | 14.1 | 19.2 | 30 | 39.9 | 29.4 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 180 | 319 | 336 | 461 | 540 |
| Operating Profit | -159 | -287 | -296 | -408 | -477 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -214 | -360 | -311 | -463 | -562 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -208 | -359 | -309 | -429 | -559 |
| Minority Interest | |||||
| Equity in Affiliates | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -204 | -292 | -298 | -428 | -573 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -204 | -292 | -298 | -428 | -573 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.87 | -2.06 | -1.15 | -1.44 | -1.12 |